Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (Cisplatin, vinblastine, mitomycin-C) regimen a phase II study

Cancer

Volumn 77, Issue 11, 1996, Pages 2251-2257

  Tummarello, Diego ^a,e   Graziano, Francesco ^a   Isidori, Pierpaolo ^b   Santo, Antonio ^c   Cetto, Gianluigi ^c   Fedeli, Anna ^b   Rossi, Giorgio ^d   Cellerino, Riccardo ^a  

^a Ospedale Regionale Torrette   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Ospedale A Murri   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Biologic response modifiers; Chemotherapy; Immunotherapy; Lung neoplasms; Nonsmall cell lung cancer

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CISPLATIN; CYTOTOXIC AGENT; MITOMYCIN C; ONDANSETRON; PARACETAMOL; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; BONE MARROW DISEASES; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; HYPOTENSION; INTERLEUKIN-2; LIFE TABLES; LUNG NEOPLASMS; MIDDLE AGED; MITOMYCIN; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0030008936     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960601)77:11<2251::AID-CNCR11>3.0.CO;2-W     Document Type: Article

References (25)

1. Souquet J, Chauvin F, Boissel JP, Cellerino R, Tummarello D, Cormier Y, et al. Polychemotherapy in advanced nonsmall cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
2. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-72.
3. Rosemberg S, Lotze M, Yang J, Linehan WM, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alpha interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
4. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2a: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-21.
5. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Vuillemin RE, et al. Sequential chemoimmunotherapy with cisplatin interleukin-2 and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-80.
6. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernst M, et al. Multistitutional phase II study of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-60.
7. Atzpodien J, Kirchner H, Lopez Hannien E, Fenner M, Poliwoda H. Alpha-interferon, interleukin-2 and 5-fluorouracil as promising biochemotherapy regimen for the management of advanced renal cell carcinoma. Proc Am Soc Clin Oncol 1993;12:708.
8. Sznol M, Longo D. Chemotherapy drug interactions with biologic agents. Semin Oncol 1993;20:80-93.
9. Cameron RB, McIntosh JK, Rosemberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and recombinant hybrid interferon in the treatment of established murine hepatic metastases. Cancer Res 1988;48:5810-7.
10. Fujita J, Saijo N, Sasaki Y. Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL2) against lung cancer cell lines by human tumor clonogenic essay. Eur J Cancer Clin Oncol 1986;13:54-62.
11. Paciucci PA, Holland JF, Ryder JS, Konefal RG, Bekesi GJ, Odchimar R, et al. Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin. Cancer Treat Rev 1989;16:67-81.
12. Chachoua A, Kriegel R, Shiller J, Wadler S, Kirkwood J, Blum RH, et al. Phase II study of combination interferon beta and gamma in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1990;9:242.
13. Kriegel R, Lynch K, Kucuk O, Tester W, Chang A, Bonomi P, et al. Interleukin-2 (IL-2) therapies prolong survival in metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1991;10:246.
14. Allavena P, Pirovano P, Bonazzi C, Colombo N, Mantovani A, D'Incalci M. In vitro and in vivo effects of cisplatin on the generation of lymphokine activated killer cells. J Natl Cancer Inst 1990;82:139-42.
15. Mitchell MS. Principles of combining biomodulators with cytotoxic agents in vivo. Semin Oncol 1992;19:51-6.
16. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 1990; 335:1509-11.
17. Ratain MJ, Priest ER, Janisch L, Vogelzang NJ. A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a. Cancer 1992;7:2371-6.
18. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, et al. A randomised trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14-22.
19. Tummarello D, Isidori P, Graziano F, Mari D, Cardarelli N, Cellerino R. Chemotherapeutic treatment in unresectable non-small cell lung cancer (NSCLC): a further attempt to modulate cisplatin, vinblastine and mitomycin-C (PVM) schedule. Oncol Rep 1994;1:415-8.
20. Mountain CF. Staging of lung cancer: the new international system. Lung Cancer 1987;3:4-11.
21. World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
22. Trillet-Lenoir V, Arpin D, Mercatello A, Oskham R, Palmer PA, Souquet PJ, et al. Combination IL-2 and cisplatinum: a promising treatment for bronchioloalveolar carcinoma? Eur J Cancer 1993;29:1917-8.
23. Ouan WDY, La Barge D, Skeel RT. Chemoimmunotherapy with alpha interferon, leucovirin and 5-fluorouracil in unresectable lung cancer. Proc Am Soc Clin Oncol 1994;13:353.
24. Ardizzoni A, Salvati F, Rosso R, Bruzzi P, Rubagotti A, Pennucci MC, et al. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Cancer 1993;72:2929-35.
25. Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, et al. A randomised study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as a first line therapy for advanced non-small cell lung cancer. Tumori 1994;80:464-7.